Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877500 · ClinicalTrials.gov registry record · Phase 2
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
A Phase 2 study of Invasive Breast Carcinoma and HER2/Neu Negative, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 3
- Study locations
NCT00877500 is a Phase 2 study of Invasive Breast Carcinoma and HER2/Neu Negative that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 116 participants, below the 483-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00877500, a Phase 2 study of Invasive Breast Carcinoma and HER2/Neu Negative, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase II trial studies how well ixabepilone compared with standard of care works in treating patients with HER2/Neu negative breast cancer that remains after undergoing systemic therapy. Ixabepilone works by blocking cell division which may cause cancer cell death.
Conditions Studied
Interventions
- OTHER Best Practice
- DRUG Ixabepilone
Study Locations (3)
Texas
- Lyndon Baines Johnson General Hospital - Houston
- M D Anderson Cancer Center - Houston
Illinois
- Advocate Christ Medical Center - Oak Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2009-03-30 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00877500
The ClinicalTrials.gov registry entry for NCT00877500 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (76% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Best Practice is the first listed.
NCT00877500 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT00877500 about?
NCT00877500 is a clinical study titled "Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy". This phase II trial studies how well ixabepilone compared with standard of care works in treating patients with HER2/Neu negative breast cancer that remains after undergoing systemic therapy. Ixabepilone works by blocking cell division which may cause cancer cell death.
What is the current status of trial NCT00877500?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2009-03-30. Estimated completion is 2026-12-31.
What conditions does trial NCT00877500 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, HER2/Neu Negative, Bilateral Breast Carcinoma.
What interventions are being tested in trial NCT00877500?
The interventions under investigation include: Best Practice (OTHER), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00877500?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00877500 being conducted?
This trial has 3 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
ACTIVE NOT RECRUITING · Phase 2
-
Metformin and Nightly Fasting in Women With Early Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.